BDC Laboratories Introduces Software to Simplify Complex GOA Determination for Prosthetic Heart Valves

Statys® GOA makes it possible to perform quantitative GOA analysis

Statys® GOA software

Biomedical Device Consultants and Laboratories (BDC Laboratories) introduced its Statys® GOA software today at MD&M West. This equipment-agnostic program simplifies and automates geometric orifice area (GOA) analysis in prosthetic heart valves.

GOA analysis is a multi-dimensional imaging challenge because heart valve substitutes have complex geometries and perform nuanced movements. Statys® GOA is the first purpose-built software for quantitative comparison of heart valve leaflet opening area between hydrodynamic testing and accelerated wear testing. It’s designed to help engineering teams better comply with ISO 5840.

Learn more about the software here: https://www.bdclabs.com/testing-equipment/statys-goa-software/

Analyzes Videos and Still Images

Statys® GOA automatically analyzes video and still images, overlays boundaries, and determines the GOA for each frame, making analysis efficient, accurate, and simple. Image contrast is crucial in GOA analysis because, without clear differentiation between the leaflet edges and the background, it’s challenging to achieve accurate measurements using edge detection. With multiple algorithms for tailoring analysis and correcting image quality, it’s easy to fix less-than-ideal lighting conditions that traditionally confound these measurements.

With an intuitive interface and automated report generation, it’s easy for anyone on the team to keep track of test results and avoid knowledge transfer gaps.

A Proven Path to GOA Analysis

“This software takes an esoteric, complex measurement and simplifies it,” said Craig Weinberg, PhD, Chief Technology Officer, BDC Laboratories. “It’s a very purpose-developed software. Statys® GOA does one thing really well—and that’s quantifying the opening area of a valve throughout the cardiac cycle.”

Today, some engineering teams create their own GOA analysis algorithms in general-purpose software platforms. With Statys® GOA, BDC Laboratories is leveraging decades of experience to ensure efficient and insightful GOA analysis, even for teams with limited resources.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”